Lotus Pharmaceuticals, a subsidiary of Alvogen has launched generic drug Vinorelbine in Europe. The Vinorelbine soft capsule is available in three dosage forms. This includes 20 mg, 30 mg, and 80 mg. The product is a generic version of Navelbine Softgel capsule which is a registered product of Pierre Fabre. This is a French pharmaceutical and dermo-cosmetics group. The generic drug Vinorelbine is available in 23 countries in the world. However, it’s the first launch of a generic version of Novelbine across Europe including countries. These countries include France, Germany, Italy, Spain, the UK, Romania, Portugal, and Hungary. The product is fully developed in house in Taiwan by a subsidiary of Alvogen.
Vinorelbine is an anti-cancer chemotherapy drug and classified as a plant alkaloid. Navelbine is also known as cytotoxic or antineoplastic drug. Vinorelbine is a new vinca alkaloid with better efficacy compared to older available drugs. These drugs include vinblastine, vincristine, and vindesine. The Vinorelbine is particularly indicated and approved for the treatment of advanced non-small-cell lung cancer (NSCLC) and advanced breast cancer. Some healthcare providers also used the drug for the treatment of Hodgkin’s disease. It is also used for treatment of ovarian cancer. In combination with cisplatin, the Vinorelbine is also used for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Advanced breast cancer or regional recurrence that spread in the lymph nodes and tissues under the breastbone and around neck, chest. Whereas secondary breast cancer has spread to the other parts of the human body, also name as stage 4, advanced, or metastatic breast cancer.
Alvogen is a privately owned pharmaceutical company extensively focusing on development, manufacturing, and sale of branded, generic, over-the-counter (OTC) brands. The company also offer biosimilar products for patients around the globe. The company has a wide footprint and operates in 35 countries. Company has four development and manufacturing hubs in Korea, the U.S., Taiwan, and Romania. Alvogen has a vast product pipeline of in-house generic projects including soft gels, oral oncology portfolio, value-added generics, and hormones.